When Patients Win, We All Win

Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects

EXPLORE OUR CLINICAL TRIALS


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

August 10, 2016

Webcast: Q2 2016 Quarterly Business Update Conference Call

Provectus will hold its 2016 second quarter business update conference call on August 10, 2016 at 4 p.m. (EDT).

July 11, 2016

Intralesional agents show promise in melanoma but may serve 'narrow clientele'

An article appearing in Healio's HemOnc Today discusses promising clinical results of PV-10 and other intratumoral agents that are being investigated for the treatment of melanoma, including combination therapies that are being investigated, such as PV-10 with pembrolizumab.

July 7, 2016

HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting

An article appearing in the Conference News section of Oncology News Magazine (Vol. 11, Issue 3) covers the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting.

June 8, 2016

2016 BIO International Convention Presentation Slides Available

Provectus presented at the 2016 BIO International Convention in San Francisco on June 8, 2016.

June 6, 2016

A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach

An article appearing on CancerNetwork discusses Dr. Sanjiv Agarwala's review of intralesional therapies for melanoma publishd in the May 2016 edition of Oncology.

June 2, 2016

Webcast: 2016 Marcum Microcap Conference Presentation

Provectus presented at the 2016 Marcum Microcap Conference in New York on June 2, 2016.

May 18, 2016

CHINABIO Partnering Forum 2016 Presentation Slides Available

Peter Culpepper, COO and interim CEO, presented at CHINABIO Partnering Forum 2016 in Suzhou, China on May 18, 2016.

May 16, 2016

Video: SNNLive Interviews Peter Culpepper at Growth Capital Expo 2016

SNNLive interviews Peter Culpepper at Growth Capital Expo 2016.

May 10, 2016

Webcast: Q1 2016 Quarterly Business Update Conference Call

Provectus will hold its 2016 first quarter business update conference call on May 10, 2016 at 4 p.m. (EDT).

May 5, 2016

Video: Peter Culpepper Interviewed at the Vatican's 2016 Cellular Horizons Conference

Peter Culpepper, interim CEO + COO, discussed Provectus' investigational cancer drug PV-10 during an interview at the Vatican's 2016 Cellular Horizons Conference.

May 4, 2016

Growth Capital Expo 2016 Presentation Webcast and Slides Available

Slides from the presentation at Growth Capital Expo 2016 are now available.

April 12, 2016

Developments in Intralesional Therapy for Metastatic Melanoma

An article appearing in Cancer Control summarizes relevant medical literature regarding the use of intralesional therapies in metastatic melanoma.

April 6, 2016

The Checkpoint Immunotherapy Revolution

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

March 30, 2016

Webcast: Quarterly Year-End 2015 Financial Business Update Conference Call

Provectus will hold its quarterly year-end 2015 financial business update conference call at 4 p.m. (EDT) March 30, 2016.

March 28, 2016

BioPharma Asia Convention 2016 Presentation Slides Available

On March 23, 2016, Provectus Biopharmaceuticals presented at the BioPharma Asia Convention in Suntec City, Singapore.

March 21, 2016

Intralesional therapy 'here to stay' for melanoma

An article appearing on Healio reports on a presentation made by Sanjiv Agarwala, MD at the HemOnc Today Melanoma and Cutaneous Malignancies conference in which he discusses intralesional therapies for treating melanoma.

March 16, 2016

Provectus audit questions former CEO's travel-expense reimbursements

An article appearing in the Knoxville News Sentinel reports on the findings of an audit ordered by Provectus' board of directors concluding that there were irregularities connected with the reimbursement of travel expenses for former Chairman and Chief Executive Officer Dr. H. Craig Dees.

March 16, 2016

Webcast: Q4, Year-End 2015 Quarterly Business Update Conference Call

Provectus will hold its fourth quarter, year-end 2015 business update conference call at 4 p.m. (EDT) March 16, 2016.

March 1, 2016

Red Dye May be Effective Melanoma Treatment

An article appearing on BioPharm International discusses how the dye Rose Bengal was discovered to be a potential treatment for melanoma.

March 1, 2016

Webcast: Business Update Conference Call

Provectus Provectus will hold a conference call at 4 PM Eastern Standard Time, on Tuesday, March 1, 2016 to discuss recently announced changes in the Company's leadership stemming from the resignation of H. Craig Dees, PhD, as Chairman and CEO.

more...

PRESS RELEASES

August 25, 2016

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million

Provectus today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock.

August 24, 2016

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

August 23, 2016

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs

Provectus today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

August 9, 2016

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results

Provectus today announced its financial results for the quarter ended June 30, 2016.

August 1, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress

Provectus today announced that a poster presentation titled "Intralesional rose bengal for stage III and IV melanoma" is to be presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in Copenhagen, Denmark.

July 20, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 second quarter business update conference call on Wednesday, August 10, 2016 at 4 pm Eastern Daylight Time.

July 18, 2016

Provectus Biopharmaceuticals Receives Patent Allowance for Use of Halogenated Xanthenes in Pharmaceutical Compositions and as Medicaments

Provectus today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The allowed claims cover use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.

July 14, 2016

Provectus Biopharmaceuticals Establishes Australian Subsidiary

Provectus today announced that it has formed an Australian subsidiary, Provectus Biopharmaceuticals Australia Pty Ltd. In addition, the Company is opening a Sydney office in New South Wales.

July 13, 2016

Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting

Provectus today announced that data on PV-10 as a treatment for melanoma was presented June 30, 2016 at the 6th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

July 12, 2016

Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at European Society for Medical Oncology 2016 Congress

Provectus today announced that the European Society for Medical Oncology's Scientific Committee has accepted an abstract for a poster presentation detailing the use of PV-10 as a treatment for stage III and IV melanoma as part of ESMO's 2016 Congress.

June 9, 2016

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online

Provectus today announced that the poster presented at the Annual Meeting of the American Society of Clinical Oncology is now available online.

June 7, 2016

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology

Provectus today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology.

June 7, 2016

Provectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA

Provectus today announced that it will present at the 2016 BIO International Convention in San Francisco, CA.

June 1, 2016

Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page

Provectus announced today the launch of its newly redesigned website at www.Provectusbio.com as well as the company's official Facebook page at www.facebook.com/Provectusbio.

May 19, 2016

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma

Provectus today announced the availability of an abstract titled "A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma" that has been published in conjunction with the annual meeting of the American Society of Clinical Oncology ("ASCO") being held in Chicago June 3-7, 2016.

May 19, 2016

Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting

Provectus today announced the availability online of an abstract titled "Intralesional rose bengal for treatment of melanoma" to be presented as a poster at the annual meeting of the American Society of Clinical Oncology ("ASCO") being held in Chicago June 3-7, 2016.

May 13, 2016

Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10's Immuno-Ablative Mechanism of Action

Provectus today announced that an article has been published detailing the immuno-ablative mechanism of action of PV-10, the Company's novel investigational drug for cancer.

May 10, 2016

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results

Provectus today announced its financial results for the first quarter 2016 ended March 31, 2016.

May 4, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.

April 28, 2016

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery

Provectus announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.

more...